Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michiel E H Hemels

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Journal of Medical Economics|September 6, 2013
Validation of an economic model of paliperidone palmitate for chronic schizophreniaThomas R Einarson, Michiel E H Hemels
The Annals of Pharmacotherapy|August 28, 2002
Increased use of antidepressants in Canada: 1981-2000Michiel E H Hemels, Gideon Koren, Thomas R Einarson
Vaccine|October 12, 2004
Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, CanadaMichael Iskedjian, John H Walker, Michiel E H Hemels
Clinical Therapeutics|June 1, 2005
A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United KingdomAlan G Wade, Idris Toumi, Michiel E H Hemels
Current Medical Research and Opinion|May 19, 2005
A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UKAlan G Wade, Idris Toumi, Michiel E H Hemels
Clinical Therapeutics|March 15, 2005
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in BelgiumKoen Demyttenaere, Michiel E H Hemels, Joumana Hudry, et al.
The Annals of Pharmacotherapy|April 29, 2004
Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depressionMichiel E H Hemels, Siegfried Kasper, Evelyn Walter, et al.
Current Medical Research and Opinion|June 18, 2004
Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in AustriaMichiel E H Hemels, Siegfried Kasper, Evelyn Walter, et al.
Journal of Medical Economics|March 5, 2015
Utilities for asthma and COPD according to category of severity: a comprehensive literature reviewThomas R Einarson, Basil G Bereza, T Anders Nielsen, et al.
The Annals of Pharmacotherapy|November 25, 2003
Meta-analysis of placebo rates in major depressive disorder trialsPieter Stolk, Maarten J Ten Berg, Michiel E H Hemels, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Journal of Medical Economics|September 6, 2013
Validation of an economic model of paliperidone palmitate for chronic schizophreniaThomas R Einarson, Michiel E H Hemels
The Annals of Pharmacotherapy|August 28, 2002
Increased use of antidepressants in Canada: 1981-2000Michiel E H Hemels, Gideon Koren, Thomas R Einarson
Vaccine|October 12, 2004
Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, CanadaMichael Iskedjian, John H Walker, Michiel E H Hemels
Clinical Therapeutics|June 1, 2005
A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United KingdomAlan G Wade, Idris Toumi, Michiel E H Hemels
Current Medical Research and Opinion|May 19, 2005
A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UKAlan G Wade, Idris Toumi, Michiel E H Hemels
Clinical Therapeutics|March 15, 2005
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in BelgiumKoen Demyttenaere, Michiel E H Hemels, Joumana Hudry, et al.
The Annals of Pharmacotherapy|April 29, 2004
Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depressionMichiel E H Hemels, Siegfried Kasper, Evelyn Walter, et al.
Current Medical Research and Opinion|June 18, 2004
Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in AustriaMichiel E H Hemels, Siegfried Kasper, Evelyn Walter, et al.
Journal of Medical Economics|March 5, 2015
Utilities for asthma and COPD according to category of severity: a comprehensive literature reviewThomas R Einarson, Basil G Bereza, T Anders Nielsen, et al.
The Annals of Pharmacotherapy|November 25, 2003
Meta-analysis of placebo rates in major depressive disorder trialsPieter Stolk, Maarten J Ten Berg, Michiel E H Hemels, et al.
Pageof 3